Table 1 Clinical and demographic characteristics
Characteristic | H12O series (N = 251 patients) | METABRIC (hormone-positive, Lum-A or Lum-B subset) (N = 998 patients) |
|---|---|---|
Age (median, range) | 54.0 (20.2–91.0) | 63.9 (26.3–90.4) |
Tumor size | ||
 T1 | 126 (50.2%) | 440 (44.0%) |
 T2 | 96 (38.2%) | 519 (52.0%) |
 T3 | 23 (9.1%) | 36 (3.6%) |
 T4 | 6 (2.4%) | N/A** |
 N/A | 0 (0%) | 5 (0.5%) |
Nodal status | ||
 N0 | 108 (43.1%) | 540 (54.0%) |
 N1 | 85 (33.9%) | 313 (31.3%) |
 N2 | 38 (15.1%) | 105 (10.5%) |
 N3 | 20 (7.9%) | 40 (4.0%) |
Grade | ||
 G1 | 63 (25.1%) | 127 (12.7%) |
 G2 | 126 (50.2%) | 502 (50.3%) |
 G3 | 62 (24.7%) | 326 (32.6%) |
 N/A | 0 (0%) | 44 (4.4%) |
Lum-A/B (defined by Ki67% staining) | ||
 < 15% (Lum-A) | 124 (49.4%) | N/A |
 > 14% (Lum-B) | 127 (50.6%) |  |
Lum-A/B (defined by PAM-50) | ||
 Lum-A | N/A | 635 (63.6%) |
 Lum-B |  | 363 (36.4%) |
Adjuvant/neoadjuvant chemotherapy | ||
 No | 63 (25.1%) | 920 (92.2%) |
 Yes | 188 (74.9%) | 78 (7.8%) |
CMF or capecitabine | 38 (15.1%) | 14 (1.4%) |
Anthracycline based | 87 (34.7%) | 38 (3.8%) |
Taxane based | 63 (25.1%) | 4 (0.4%) |
Other | 0 (0%) | 22 (2.2%) |
Adjuvant hormonal therapy | ||
 No | 13 (5.2%) | 273 (27.4%) |
 Yes | 238 (94.8%) | 725 (72.6%) |
FGFR1 amplified* | 195/251 available (77.7%) | 998/998 available (100%) |
 No | 172 (88.2%) | 922 (92.4%) |
 Yes | 23 (11.8%) | 76 (7.6%) |
FGFR1 RNAscope positivity | 165/251 available (65.7%) | Â |
 Negative (0, 1+, or 2+) | 137 (83%) | N/A |
 Positive (3+ or 4+) | 28 (17%) | N/A |
Relapse | ||
 No | 169 (73.3%) | 627 (62.8%) |
 Yes | 82 (32.7%) | 370 (37.1%) |
 N/A | 0 (0%) | 1 (0.1%) |